Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Research and Innovation Action · Running

IMPACT- AML Master Framework and Pragmatic Clinical Trial for Relapse or Refractory Acute Myeloid Leukemia

Coordinator
Istituto Romagnolo per Lo Studio Dei Tumori Dino Amadori - Irst SRL, Italy
Runs
1 April 2023 to 31 March 2028
Status
Running
EU funding
€6.0m
Total cost
€6.0m
Partners
20 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101104421

What the project is doing

In the project's own words, from its summary on CORDIS.

In IMPACT-AML, a multidisciplinar R/R AML represents a model of high-impact disease, in which no standard of care exists, and where we have an urgent need for new evidence on possible therapies; AML offers the setting in which methodological innovation will combine powerful instruments of clinical trials with personalized medicine through academic efforts. Hereby, we propose to create an inclusive master framework for relapsed or refractory acute myeloid leukemia (STREAM) to include patients with R/R AML across Europe proficiently acquire an unselected population for clinical trials and monitor outcomes including neglected cohorts.

Thereafter we will conduct a prospective randomized pragmatic clinical trial (RPCT) that will compare the classical “high intensity” rescue chemotherapy with biology-driven, “low intensity” rescue to obtain “real world” data on the benefit of one of the two different strategies in term of survival also considering patients and caregivers preferences, patient-reported outcomes (PRO), accessibility, affordability, and social cost.

RPCT will aim to evaluate the effectiveness of real-world clinical alternatives in routine care. In addition to retaining the high internal validity of traditional randomized trials, it will maximize external validity, i. e. generalizability of results to many settings. In this context, the inclusion of an RPCT in the master framework will allow a dynamic inclusion and the collection of the excluded population as an instrument to predict the real-life applicability of clinical trial results.

We will offer Europe results from an ambitious project, that will go beyond the state of the art in R/R AML demonstrating the superiority of a strategy in a first-of-his-kind clinical trial, providing strong data that will be delivered to national health care providers, policymakers, and health authorities data on optimized and affordable treatment for R/R AML and promoting the implementation of the selected better option.

This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.

Topics

Who is involved

OrganisationCityCountryRole
Istituto Romagnolo per Lo Studio Dei Tumori Dino Amadori - Irst SRLMeldolaItalyCoordinator
TimelexBruxelles / BrusselBelgiumParticipant
Kypriako Idryma Erevnon Gia Ti Myiki DistrofiaAgios DometiosCyprusParticipant
Ceska Leukemicka Skupina - Prozivot, Z SBrnoCzechiaParticipant
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Gpoh Gemeinnutzige GmbHBerlinGermanyParticipant
Martin-Luther-Universitat Halle-WittenbergHalleGermanyParticipant
Medizinische Hochschule HannoverHannoverGermanyParticipant
Osho, Ostdeutsche Studiengruppe Hamatologie Und Onkologie E.v.LeipzigGermanyParticipant
Padiatrisches Forschungsnetzwerk gGmbHEssenGermanyParticipant
Stiftung Eln FoundationWeinheimGermanyParticipant
Fundacio Hospital Universitari Vall D'hebron - Institut De RecercaBarcelonaSpainParticipant
Fundacion De Investigacion Biomedica De SalamancaSalamancaSpainParticipant
Fundacion Instituto De Estudios De Ciencias De La Salud De Castilla Y LeonSoriaSpainParticipant
Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad ValencianaValenciaSpainParticipant
Alma Mater Studiorum - Universita Di BolognaBolognaItalyParticipant
Fondazione G.i.m.em.a. - Franco Mandelli OnlusRomaItalyParticipant
Fondazione Toscana Life SciencesSienaItalyParticipant
Ospedale Pediatrico Bambino GesuRomaItalyParticipant
Lietuvos Sveikatos Mokslu Universiteto Ligonine Kauno KlinikosKaunasLithuaniaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI